Paragraph IV Litigation and IPRs

Interplay Between Paragraph IV Litigation and IPRs, Multiple Generic Challengers, Key Issues in IPRs

Recording of a 90-minute CLE webinar with Q&A


Conducted on Thursday, April 5, 2018

Recorded event now available

or call 1-800-926-7926

This CLE webinar will guide counsel on pharmaceutical-related patent challenges. The panel will discuss the interplay between Paragraph IV litigation and post-grant proceedings, and where multiple generic challengers fit in the exclusivity scheme. The presenters will also examine critical issues in IPR challenges involving pharmaceutical patents.

Description

Inter partes review proceedings (IPRs) are a powerful tool for companies to challenge pharmaceutical patents. The number of pharmaceutical-related challenges using the IPR process is expected to continue to climb given the advantages that IPRs offer compared to district court litigation, as well as the increasing number of abbreviated new drug applications filed with the FDA.

All of this is based on the lower standard of proof, a broader standard for claim construction, and a panel of judges with technical expertise as compared to Federal District Court. As a result, the IPR process is an attractive option for challenging pharmaceutical patents over litigating them in Federal Court. IPR challenges alone or in conjunction with district court litigation are becoming increasingly common with respect to pharmaceuticals.

Listen as our authoritative panel of patent attorneys and litigators examine the interplay between Paragraph IV litigation and post-grant proceedings. The panel will also discuss key issues in post-grant challenges involving pharmaceutical patents as well as how pharmaceutical patents fare in post-grant challenges.

READ MORE

Outline

  1. Interplay between Paragraph IV litigation and IPRs
  2. Multiple generic challengers and exclusivity
  3. Pharmaceutical patents in post-grant challenges
  4. Key issues in post-grant challenges involving pharmaceutical patents

Benefits

The panel will review these and other key issues:

  • Where do multiple generic challengers fit into the exclusivity scheme?
  • How do pharmaceutical patents fare in post-grant challenges in comparison to all patents?
  • What are the crucial issues in post-grant challenges involving pharmaceutical patents?

Faculty

Dunston, Erin
Erin M. Dunston

Shareholder
Buchanan Ingersoll & Rooney

Ms. Dunston focuses on inter partes reviews, interferences, district court litigation, opinions, and prosecution...  |  Read More

Fedowitz, Matthew
Matthew L. Fedowitz

Shareholder
Buchanan Ingersoll & Rooney

Mr. Fedowitz has a particular expertise in the pharmaceutical, life science and medical device fields. His practice...  |  Read More

Markowski, Mythili
Mythili Markowski, Ph.D.

Buchanan Ingersoll & Rooney

Dr. Markowski focuses her practice on intellectual property law, where she has experience in IP procurement,...  |  Read More

Other Formats
— Anytime, Anywhere

Strafford will process CLE credit for one person on each recording. All formats include program handouts. To find out which recorded format will provide the best CLE option, select your state:

CLE On-Demand Video

$297

Download

$297